Investment Thesis
VYNE demonstrates adequate financial cushion with $24.6M cash and zero debt, but faces critical commercialization failure with near-zero revenue ($86K) despite significant operating losses (-$3.8M) and negative cash flow (-$4.1M). For a pharmaceutical company, minimal revenue suggests failed product launches or stalled pipeline with approximately six years of runway at current burn rate before capital depletion.
Strengths
- Strong cash position of $24.6M with no long-term debt provides financial runway
- Excellent liquidity metrics (20.86x current ratio) enable debt service and operations
- Positive stockholders' equity of $24.6M maintains solvency and balance sheet integrity
Risks
- Near-zero revenue ($86K) indicates failed commercialization or stalled product adoption for a pharmaceutical company
- Significant operating losses (-$3.8M) and negative free cash flow (-$4.1M) destroy shareholder value with ROE of -14.6% and ROA of -13.9%
- Finite cash runway of approximately six years at current burn rate without revenue growth creates existential timeline pressure
Key Metrics to Watch
- Revenue growth trajectory and product commercialization progress
- Operating cash flow trend to assess if burn rate is accelerating or stabilizing
- Cash balance depletion rate and remaining runway before capital exhaustion
Financial Metrics
Revenue
86.0K
Net Income
-3.6M
EPS (Diluted)
$-0.08
Free Cash Flow
-4.1M
Total Assets
25.9M
Cash
24.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,437.2%
Net Margin
-4,168.6%
ROE
-14.6%
ROA
-13.9%
FCF Margin
-4,745.3%
Balance Sheet & Liquidity
Current Ratio
20.86x
Quick Ratio
20.86x
Debt/Equity
0.00x
Debt/Assets
4.8%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:40:41.704157 |
Data as of: 2026-03-31 |
Powered by Claude AI